Product Information
HADLIMA(CF) 40 MG/0.4 ML SYRINGE is a brand biologic product labeled by Organon LLC, priced at $1258.3781 per ML under NDC 78206018601. Its NADAC has been published 94 times since Dec 18, 2024.
Strength
40 mg/.4mL
Manufacturer
Organon LLCNDC
78206018601
Classification
Brand Biologic
Dosage Form
SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
ADALIMUMABApproval Type
Biologic (BLA)
FDA Application
BLA761059On Market Since
7/1/2023
Pharmacological Classes
Price Statistics
The NADAC for HADLIMA(CF) 40 MG/0.4 ML SYRINGE has been published 94 times since Dec 18, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $1258.3781 per ML |
|---|---|
| All-time high | $1260.7425 (Feb 11, 2026) |
| All-time low | $1254.6130 (Aug 19, 2026) |
| 52-week high | $1260.7425 |
| 52-week low | $1254.6130 |
| Median price | $1258.5745 |
| Average price | $1258.0291 |
| Largest weekly change | +0.3% (Sep 23, 2026) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 50% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Organon LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
adalimumab-bwwd market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tumor Necrosis Factor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HADLIMA(CF) 40 MG/0.4 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for HADLIMA(CF) 40 MG/0.4 ML SYRINGE, manufactured by Organon LLC, is $1258.3781 per ML (NDC 78206018601), effective Sep 30, 2026.
How has the price of HADLIMA(CF) 40 MG/0.4 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for HADLIMA(CF) 40 MG/0.4 ML SYRINGE has held within roughly two percent of its current level. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for HADLIMA(CF) 40 MG/0.4 ML SYRINGE?
Since Dec 18, 2024, the NADAC for HADLIMA(CF) 40 MG/0.4 ML SYRINGE has ranged from a low of $1254.6130 (Aug 19, 2026) to a high of $1260.7425 (Feb 11, 2026), with a median of $1258.5745 per ML.
Are there cheaper alternatives to HADLIMA(CF) 40 MG/0.4 ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HADLIMA PUSHTOUCH 40 MG/0.8 ML, is $623.4931 per ML — about 50% below HADLIMA(CF) 40 MG/0.4 ML SYRINGE.
Who manufactures HADLIMA(CF) 40 MG/0.4 ML SYRINGE?
HADLIMA(CF) 40 MG/0.4 ML SYRINGE (NDC 78206018601) is labeled by Organon LLC, and CMS classifies it as a brand biologic product.